A Phase III, Randomized, Double-blind, Placebo-controlled International Multicenter Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light Vector Vaccine in the Parallel Assignment of the Subjects in Prophylactic Treatment for SARS-СoV-2 Infection
Latest Information Update: 07 Feb 2023
At a glance
- Drugs COVID-19 vaccine-Gamaleya National Research Center of Epidemiology and Microbiology (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Registrational
- Acronyms SPUTNIK-LIGHT
- 19 Feb 2021 Status changed from not yet recruiting to recruiting.
- 18 Feb 2021 New trial record